AI platform developed to reveal how bacteria infect intestines
A new artificial intelligence (AI) method has been created to uncover which proteins enable bacteria to infect human intestines.
List view / Grid view
A new artificial intelligence (AI) method has been created to uncover which proteins enable bacteria to infect human intestines.
Researchers have used cryo-EM to show that a new nanobody cocktail can bind to the S protein of SARS-CoV-2, neutralising the coronavirus.
Scientists have developed a drug called STM2457 which inhibits a key enzyme involved in acute myeloid leukaemia.
The UK has launched the Pandemic Preparedness Partnership which will advise the G7 Presidency how to reduce vaccine development time from 300 to 100 days.
Researchers have shown in mice that macrophages play a role in controlling blood flow and healing following tissue damage.
An AI software called ZeroCostDL4Mic has been developed by researchers to enable other scientists to analyse images from microscopy studies.
Scientists have said that researchers need to be more aware of unintended mutations to human embryos following CRISPR-Cas9 genome editing.
A candidate vaccine has shown potential against MERS in non-human primates, when administered intradermally.
Biliverdin attaches to a region of the SARS-CoV-2 Spike protein, stabilising it so that it is not able to expose its structure to antibodies, a new study has shown.
Oral doses of a new drug named CA administered to mouse models led to improvements in Alzheimer's disease, including memory.
Having synthesised the curcusone D compound, researchers demonstrated its promise as the first BRAT1 inhibitor, making it a potential cancer therapy.
A range of imaging and computational techniques were used by researchers to discover the structure of the PH domain of PLEKHA7.
Using newly developed assays, researchers have characterised the antibody response of individuals infected with SARS-CoV-2.
Researchers have developed a stem cell therapy that could treat the damage caused by dementia by launching a repair response.
Researchers have developed a platform named FAST to produce antibiotics that specifically target just the bacteria of interest.